Author(s)

Lvping Fu, Shasha Zhou, Zhiyuan Guo , Zhenqiao Kang, Weihua Qi

Corresponding Author

Shasha Zhou

Abstract

Objective: It is to observe the efficacy and safety of domestic recombinant human endostatin (endo) combined with XELOX regimen (oxaliplatin + capecitabine) in the treatment of advanced gastric cancer. Methods: 104 confirmed gastric cancer patients were randomly divided into two groups: a control group of 47 patients, using XELOX regimen: oxaliplatin 130 mg / m2, d1; capecitabine 1 000 mg / m2, d1 ～ 14,4 One week is a course of treatment; 57 cases in the treatment group have the same chemotherapy regimen, dosage method, and treatment course as the control group, and daily recombinant human endostatin 7.5 mg / m2, intravenous drip from d1 to 14 d. After 2 cycles of treatment, the efficacy evaluation and the evaluation of side effects were conducted. Results: The effective rate was 59.7% in the treatment group and 30.4% in the control group. The difference between the two groups was statistically significant (χ2 = 4.6471, P <0.05). The time to disease progression (TTP) and median survival (MST) were 7.1 months and 11.8 months in the treatment group; 5.6 months and 9.6 months in the control group, and the difference was not statistically significant (P> 0.05); Compared with the control group, there was no significant increase (P> 0.05). Conclusion: Recombinant human endostatin combined with XELOX regimen is effective and safe in the treatment of advanced gastric cancer, and it is worthy of further study.

Keywords

Advanced gastric cancer; Recombinant human endostatin; Oxaliplatin